Table 1: Demographic characteristics of transplant patients between steroid, basiliximab and alemtuzumab inductions.

Steroid (n = 58) Basiliximab (n = 56) Alemtuzumab (n = 98)
Age mean ± sd (y) 48.2 ± 14.2 46.8 ± 15.4 47.3 ± 14.4
Gender (%)
male 57 54 55
female 43 46 45
Race (%)
black 60 64 62
non-black 40 36 38
BMI (kg/m2) 27.5 ± 6.6 28.2 ± 6.1 27.8 ± 5.9
Peak PRA (%) 13.2 ± 24.6 16.8 ± 27.3 14.9 ± 23.7
HLA mismatch 3.6 ± 1.5 4.3 ± 1.6 4.1 ± 1.4
Causes of ESRD (%)
diabetes 26 30 28
hypertension 40 34 37
nephritis 17 14 14
PCKD 7 9 8
others 10 13 13

CIT (hrs)

ECD (%)

16.3 ± 7.6

31

18.9 ± 6.9

39.3

17.7 ± 6.3

34.7
Significant p-values:

Peak PRA: p = 0.01 for steroid group vs. basiliximab group; p = 0.03 for basiliximab group vs. alumtuzmab group; CIT: p = 0.04 for steroid group vs. basiliximab group; p = 0.02 for basiliximab group vs. alumtuzmab group.

Non-significant p-values:

Age: p = 0.25; Gender: p = 0.47; Race: p = 0.81; BMI: p = 0.52; Cause of ESRD: p = 0.95; ECD: p = 0.49.